Effect of the FreeStyle Libre 2 Flash Glucose Monitoring System on Hyperglycemia in People With T2 Diabetes

Completed

Conditions studied: Diabetes Mellitus

In brief

A multi-center, randomized, prospective, non-significant risk study to compare the impact of the FreeStyle Libre 2 Flash Glucose Monitoring System to the current standard of care (SMBG, self-monitoring of blood glucose) on reducing time above 180 mg/dL in subjects with type 2 diabetes who are not adequately controlled on their existing oral anti-diabetes medication regimen.

Key facts

Study ID

NCT04604093

Run by

Abbott Diabetes Care

People needed

358

Starts

2020-10-20

Expected to finish

2023-03-30

Last updated by the study team

2023-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must be at least 18 years of age.
• Subject must have HbA1c of > 7.5% at screening
• Subject has 35% or more time spent above 180 mg/dL during the screening phase.
• Subject must have had a diagnosis of type 2 diabetes for at least six (6) months prior to enrollment.
• Subject has been prescribed at least one capillary blood test every day for self-management of blood glucose (SMBG) to manage their diabetes.
• Subject must be on at least one (1) oral anti-diabetes medication.
• Subject must be able to read and understand English.
• In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
• Subject is willing to make diet and lifestyle changes in response to education and glucose data
• Subject must be available to participate in all study visits.
• Subject must be willing and able to provide written signed and dated informed consent.

You may not qualify if…

• Subject is currently on any form of insulin therapy.
• Subject has used an unblinded continuous glucose monitor (CGM) in the 3 months prior to enrollment.
• Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.
• Subject is known to be pregnant at the time of study enrollment (applicable to female subjects only).
• Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.
• Subject has concomitant medical condition which, in the opinion of the investigator, could present a risk to the safety or welfare of the subject or study staff.
• Subject is currently undergoing dialysis and/or has end stage renal disease.
• Subject is currently participating in another interventional clinical trial.
• Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Where it is running

• Valley Research — Fresno, California, United States
• CEDE (Center of Excellence in Diabetes and Endocrinology) — Sacramento, California, United States
• Metabolic Research Institute — West Palm Beach, Florida, United States
• Billings Clinic — Billings, Montana, United States
• Palm Research Center — Las Vegas, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.